Research analysts covering BetterLife Pharma.
Recent press releases and 8-K filings for BETRF.
BetterLife Pharma Inc. Reports Q2 2026 Financials and Product Development Updates
BETRF
Earnings
Profit Warning
New Projects/Investments
- BetterLife Pharma Inc. reported no revenue for the three and six months ended July 31, 2025, incurring net losses of $504,111 and $711,166, respectively, which were lower than the prior comparable periods.
- The company's operating expenses significantly decreased to $521,805 for the three months and $832,488 for the six months ended July 31, 2025, primarily due to minimized discretionary consulting, professional, and research and development expenses.
- As of July 31, 2025, BetterLife Pharma Inc. had an accumulated deficit of $119,301,932 and a working capital deficiency of $5,757,486, leading to substantial doubt about its ability to continue as a going concern.
- The company is actively developing several drug candidates, including BETR-001 and BETR-002 (both preclinical for mental health/anxiety), and MM-001 (clinical stage for CIN) and MM-003 (preclinical for viral infections), with regulatory statuses and development timelines under ongoing assessment.
Sep 29, 2025, 9:03 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more